October 21, 2026 Page

CURRENT AND PROJECTED ACCRUAL¹

BY SWOG AND NON-SWOG INSTITUTIONS

TO SWOG-COORDINATED NCTN TRIALS

BY COMMITTEE

81% of Calendar Year is Past

Committee Annual
Base
Accrual²		 Projected
2026
Accrual		 2026
Projected
Percentage
of Base Accrual		 2026
Accrual
to date		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months
BREAST 472 1015 214% 815 543 987
ERLYTX 54 61 113% 49 7 59
GI 100 97 97% 78 -3 96
GU 256 299 116% 240 43 295
LEUK 354 761 214% 611 407 747
LUNG 817 556 68% 446 -261 556
LYMPH 181 374 206% 300 193 356
MELAN 364 0 0% 0 -364 0
MMYEL 192 108 56% 87 -84 102
MULT 25 42 169% 34 17 47
Total 2815 3313   2660 498 3245

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 21, 2026 Page

CURRENT AND PROJECTED ACCRUAL¹

BY SWOG AND NON-SWOG INSTITUTIONS

TO SWOG-COORDINATED NCORP TRIALS

BY COMMITTEE

81% of Calendar Year is Past

Committee Annual
Base
Accrual²		 Projected
2026
Accrual		 2026
Projected
Percentage
of Base Accrual		 2026
Accrual
to date		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months
CCD 578 208 36% 167 -370 196
PEOLC 52 29 55% 23 -23 59
PREV 169 0 0% 0 -169 0
SXQOL 958 597 62% 479 -361 589
Total 1757 834   669 -923 844

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 21, 2026 Page

CURRENT AND PROJECTED ACCRUAL

BY SWOG AND NON-SWOG INSTITUTIONS

TO SWOG CTP TRIALS

BY STUDY

81% of Calendar Year is Past

Committee Study Projected
2026
Accrual		 2026
Accrual
to date		 Accrual
Last
12 Months
ERLYTX 21CTP.HN01 14 11 11
LEUK 21CTP.LEUK01 10 8 8
Total   24 19 19

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 21, 2026 Page

CURRENT AND PROJECTED ACCRUAL¹

BY SWOG INSTITUTIONS

TO ANY NCTN TRIAL

BY COMMITTEE

81% of Calendar Year is Past

Committee Annual Base Accrual² Projected
2026
Accrual		 2026
Projected
Percentage
of Base Accrual		 2026
Accrual
to date		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months
BREAST 352 694 197% 557 342 700
ERLYTX 42 47 111% 38 5 45
GI 157 131 83% 105 -26 126
GU 399 305 76% 245 -94 300
LEUK 182 341 187% 274 159 344
LUNG 551 366 66% 294 -185 364
LYMPH 173 293 169% 235 120 282
MELAN 228 7 3% 6 -221 8
MMYEL 135 70 51% 56 -65 65
MULT 14 19 136% 15 5 19
OTHER 57 64 111% 51 7 61
Total 2290 2337   1876 47 2314

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 21, 2026 Page

CURRENT AND PROJECTED ACCRUAL¹

BY SWOG INSTITUTIONS

TO ANY NCORP TRIAL

BY COMMITTEE

81% of Calendar Year is Past

Committee Annual Base Accrual² Projected
2026
Accrual		 2026
Projected
Percentage
of Base Accrual		 2026
Accrual
to date		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months
CCD 534 162 30% 130 -372 159
GI 0 1 .% 1 1 1
PEOLC 37 26 70% 21 -11 50
PREV 341 222 65% 178 -119 228
SXQOL 665 492 74% 395 -173 479
Total 1577 903   725 -674 917

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 21, 2026 Page

SWOG OPEN AND TEMPORARILY CLOSED NCTN STUDIES

Comm. Phase Study Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure		 Proj.
Study
Duration
(Years)
BREAST III S2206: Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva 10/30/2023 35 427 960 11.5 Aug-2030 6.8
    S2212: Breast, TNBC, Neoadj Chemo + Pembro 07/21/2023 39 1754 2400 70.8 Jul-2027 4.0
    S2511: Brst, de novo StgIV oligo, locoreg tx vs SOC 08/18/2026 2 0 534      
ERLYTX II SN2426: cSCC, IC Met/Inop, Amivantamab v Cetuximab 01/28/2026 8 12 86 1.5 Nov-2030 4.8
  II-III S2012: Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo 12/02/2021 58 170 189 3.3 Mar-2027 5.3
  III S2505: Sarcoma, Stg II-IIIB, Surg + Short vs Std RT 07/06/2026 3 0 296 0.3 > 15 Yrs > 15 Yrs
GI II S2104: Panc,Resect High-risk,Postop Adj Chemo vs Obs 10/14/2021 60 111 154 2.8 Jan-2028 6.3
  II-III S2303: Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo 05/06/2024 29 124 224 5.5 Apr-2028 4.0
  III S2433: PANC, KRAS WT, Met, SOC Chemo +/- Panitumumab 12/26/2025 9 1 94 0.2 > 15 Yrs > 15 Yrs
GU II S2210: Pros, High Risk, BRCA, Neoadj Carbo 08/14/2023 38 7 44 0.2 > 15 Yrs > 15 Yrs
    S2427: Blad, MIBC, RT + Pembrolizumab 09/04/2025 13 60 111 8.3 Apr-2027 1.6
  III S1802: Pros, Stg IV, SST ± Surg/RT to Primary Tum 09/17/2018 97 1061 1273 7.8 Jan-2029 10.3
    S1931: RENAL, Stg IV, IO + Nephrectomy. vs IO Only 11/16/2020 71 165 336 2.7 Feb-2032 11.3
    S2312: Pros, MCRPC, Cab +/- Carb 09/03/2024 25 75 500 4.2 Apr-2035 10.6
    S2419: Renal, adv clear cell, IO +/- Biotx, BIOFRONT 04/22/2026 5 41 718 6.9 Dec-2034 8.7
LEUK II MM1OA-S03: AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena 04/01/2025 18 30 102 3.7 May-2028 3.1
    MM1OA-S04: MyeloMATCH: AML, ASTX727 + Ven (28D v 14D) 07/22/2026 2 1 126      
    MM1YA-S01: AML, High Risk, Age <60, 7+3 vs experimental 05/16/2024 29 94 335 4.2 Jul-2031 7.2
    S2507: ALL/ALAL, KMT2A-trans, Blina +/- Revumenib 09/22/2026 0 0 90      
  III S1925: CLL/SLL, Newly Dx HR, Early vs Delayed V+O 12/14/2020 70 212 247 4.8 May-2027 6.4
    S2504: Richter Trans., Untreated, R-CHOP +/- Pirto 06/01/2026 4 2 102 0.4 > 15 Yrs > 15 Yrs
  OTHER MYELOMATCH: MSRP for the NCI myeloMATCH Clinical Trials 05/16/2024 29 1367   53.3 .- . .
LUNG II S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu 04/03/2023 42 28 44 0.5 Jun-2029 6.2
    S1900K: MET Exon 14: Tepotinib +/- Ramucirumab 12/18/2023 34 32 56 1.2 Jun-2028 4.5
    S1900N: AGAs: SG alone, I alone, or SG + I 08/03/2026 2 2 117      
    S2409: ESCLC, Durvalumab +/- Biomarker Directed Tx 09/08/2025 13 19 900 2.5 > 15 Yrs > 15 Yrs
  II-III S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab 04/28/2025 17 147 378 9.7 Sep-2028 3.4
  III S2414: NSCLC, Stg II-IIIB, Durva vs Surveillance 03/14/2025 19 15 306 1.2 > 15 Yrs > 15 Yrs
  OTHER LUNGMAP: NSCLC, Adv, Master 01/28/2019 92 4153   28.7 .- . .
LYMPH II S2114: NHL, Rel/Ref, CD19 CAR-T +/- Consolidation 02/23/2023 43 257 396 7.7 Apr-2028 5.2
    S2207: LBCL, Transplant Inelig, Targeted Tx + Tafa 06/30/2023 39 43 173 0.7 > 15 Yrs > 15 Yrs
    S2506: NHL, R/R MZL, Mozun +/- Zanu or Pola 08/18/2026 2 1 138      
  III S2308: FL, LTB, Mosunetuzumab vs Rituximab 08/01/2024 26 448 600 24.3 Apr-2027 2.7
MMYEL II S2005: WM, Prev. Untreated, I/R or Z v V/R 06/24/2021 63 46 92 3.3 Nov-2027 6.4
  III S1803: MM, Maintenance, Len vs Len/Dara 06/27/2019 87 1338 1100 0.0    
    S2209: MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D 05/30/2023 40 149 510 3.5 May-2035 12.0
    S2213: AL Amyloidosis, Newly Dx, Dara-VCD v ASCT 12/01/2023 34 55 142 2.3 Nov-2029 6.0
MULT II S2101: Melan or HNSCC, Adv, Cabo + Nivo 10/14/2022 48 110 220 3.3 Jul-2029 6.8
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

October 21, 2026 Page

SWOG OPEN AND TEMPORARILY CLOSED NCORP STUDIES

Comm. Phase Study Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure		 Proj.
Study
Duration
(Years)
CCD III S1703: Met Breast, STM-monitoring v Usual Care 07/16/2018 99 477 498 3.7 Mar-2027 8.7
    S2417CD: Colrec Surv, Follow-up w/ CTAC site 08/04/2025 14 140 654 13.5 Dec-2029 4.4
    S2424CD: A-PACT vs SOC for GOC communication 06/01/2026 4 9 1000 1.9 > 15 Yrs > 15 Yrs
PEOLC III S1501: Breast Stg IV, Card Tox Obs and w/ Carvedilol 09/15/2017 109 402 491 2.2 Mar-2030 12.5
    S2408: Panc Fistula Prevention, Lanreotide 02/14/2025   63 274      
SXQOL III S2205: ICE COMPRESS: Reduction of CIPN from Taxanes 03/16/2023 43 691 777 16.0 Mar-2027 4.0
  OTHER S2013: I-CHECKIT: ICI toxicity risk prediction study 08/16/2021 62 2672 3609 33.2 Feb-2029 7.5
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

October 21, 2026 Page

SWOG OPEN AND TEMPORARILY CLOSED CTP STUDIES

Comm. Phase Study Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure		 Proj.
Study
Duration
(Years)
ERLYTX II 21CTP.HN01: HN, Recur/Met, Amivantamab + Chemo 03/05/2026 7 11 50 1.5 Dec-2028 2.8
LEUK II 21CTP.LEUK01: ALL, Ph+, Asciminib, Dasatinib and Prednisone 12/11/2025 10 8 55 1.2 Feb-2030 4.2
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.